Total net sales for 2025 increased by 0.9% to $8,325 million, with organic growth of 3.3% driven by MedSurg, Dental Solutions, and Health Information Systems. Operating income surged by 110.5% to $2,181 million in 2025, primarily due to a $1,549 million pre-tax gain from the sale of the Purification and Filtration business. Net income for 2025 was $1,556 million, a substantial increase from $479 million in 2024, leading to diluted EPS of $8.88 compared to $2.76 in 2024. The company completed the sale of its Purification and Filtration business to Thermo Fisher Scientific Inc. in September 2025 for approximately $4 billion in cash. Solventum acquired Acera Surgical, a bioscience company specializing in regenerative wound care, in December 2025 for $696 million cash, plus a potential $125 million sales-based milestone payment. A new multiyear 'Transform for the Future' restructuring program was approved in November 2025, targeting approximately $500 million in annual cost savings and an estimated $500 million in cumulative pre-tax costs. Cash flows from operating activities decreased to $369 million in 2025 from $1,185 million in 2024, impacted by higher separation costs and transition service agreement activities. Long-term debt was reduced to $5,035 million in 2025 from $7,810 million in 2024, following the repayment of $2.0 billion in senior notes and $1.07 billion in term loans.